In animals treated with the potent NEP-inhibitor phosphoramidon, the tumor-to-kidneys ratio increased to 3.8 ± 0.9 from 2.7 ± 0.4 in control group due to an increase in tumor uptake. This evidence concerns the gene MME and neoplasm.